Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-490-6 | CAS number: 107-43-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- Review article of a well-established metabolism route for betaine, oxidation product of choline within the human body.
- GLP compliance:
- no
- Species:
- human
- Sex:
- male/female
- Route of administration:
- oral: feed
- Vehicle:
- not specified
- Type:
- metabolism
- Results:
- Completely metabolized by liver and kidney cells by methylation to dimethylglycine and ultimately to serine.
- Metabolites identified:
- yes
- Details on metabolites:
- Dimethylglycine
- Conclusions:
- Betaine is completely metabolized by liver and kidney cells, a very small amount is passed in urine.
- Executive summary:
Completely metabolized by liver and kidney cells by methylation to dimethylglycine and ultimately to serine; a very small amount is passed in urine.
Reference
Description of key information
Betaine can be found in the human body as a naturally occurring substance, it is formed within the body from the oxidation of choline. Betaine (also known as trimethylglycine) is further metabolized first to dimethylglycine and ultimately to glycine and sarcosine. Betaine acts as an osmolyte and protectant against adverse phenomena within the body, and is involved in one-carbon metabolism and methylation processes. Betaine's main action is to donate a methyl group to homocysteine, which then is subsequently metabolized to methionine.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Betaine can be found in the human body as a naturally occurring substance, it is formed within the body from the oxidation of choline. Betaine acts as an osmolyte and protectant against adverse phenomena within the body, and is involved in one-carbon metabolism and methylation processes. Betaine's main action is to donate a methyl group to homocysteine, which then is subsequently metabolized to methionine. Betaine (also known as trimethylglycine) itself is metabolized first to dimethylglycine and ultimately to glycine and sarcosine.
Humans can consume betaine from normal food stuffs such as vegetables, seafood and wheat, since betaine occurs in nature mainly as protectant of stress, especially osmotic stress. Betaine is metabolized mainly by the liver but also by kidney cells. Betaine has been found safe in various nutritional and pharmacokinetic human studies, as well as in a wide range of toxicity testing in animals following OECD guidelines in GLP conditions. Betaine is used in feed for animals and is approved as a supplement or nutrient for human consumption in several geographic regions.
The emphasis of human studies has mostly been to investigate how betaine improves health, especially in the case of a metabolic disorder called homocystinuria, where betaine is approved by the US-FDA for the treatment of this disorder. When detected from serum, betaine is metabolized within 24 hours by the body (highest dose 6g, with the single dose of 50mg/kg elimination half-life was approximately 14 hours, continuous approximately 5 days). When studying the activity of the betaine metabolizing enzyme, betaine homocysteine methyltransferase (BMHT), in animals, adaptation for higher doses of betaine has been detected in rats. Excess betaine is excreted via urine. Dermal absorption of betaine is extremely low as tested in the in vitro-setting. Attachment: betaine metabolism - schematic diagram.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.